Skip to main content

Table 3 Determination of prognostic clinical factors

From: An eight-mRNA signature outperforms the lncRNA-based signature in predicting prognosis of patients with glioblastoma

Clinical characteristicsTraining set
(N = 151)
Uni-variables coxMulti-variables cox
HR95%CIP-valueHR95%CIP-value
Age (years, mean ± SD)59.82 ± 13.671.0291.014–1.0451.966 × 10− 041.0221.005–1.0391.310 × 10−02
Gender (Male/Female)97/540.8990.613–1.3205.886 × 10−01
Chemo-therapy (Yes/No/−)45/89/170.6030.397–0.9151.625 × 10− 021.7910.895–3.5859.960 × 10− 02
Drug-therapy (Yes/No/−)20/113/180.7290.431–1.2342.377 × 10−01
Immuno-therapy (Yes/No/−)2/131/180.5550.136–2.2644.050 × 10−01
Pharmaceutical-therapy (Yes/No/−)55/82/140.4190.276–0.6393.239 × 10−050.3350.169–0.6631.700 × 10−03
Targeted molecular-therapy (Yes/No/−)18/115/180.8890.519–1.5236.701 × 10−01
Radiotherapy (Yes/No/−)20/117/140.6110.346–1.0788.575 × 10−02
Risk status (High/Low)75/764.5192.963–6.8944.319 × 10−144.1792.631–6.6401.390 × 10−09
Dead (Death/Alive/−)115/36
Overall survival time (months, mean ± SD)13.26 ± 10.82
  1. SD Standard deviation, HR Hazard ratio, CI Confidential interval